Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Heavy volume @ 86 milly.
ARAV pipeline > https://aravive.com/pipeline/
FOMO / MOMO taking ARAV much higher.
Agree, very huge catalyst:
They are presenting updated clinical trial data from Batiraxcept trials in Renal and Pancreatic cancer this weekend October 20 - 24th at ESMO Congress 2023
Let's see what next week brings... this could be a banger .40 - .80 cents next week if news drops or even just on Anticipation, FOMO and whoever knows on the inside of what is to come and is loading while others are dumping in fear
> ARAV @ .24
Investors might want to bet on Aravive (ARAV), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
Shares of XRTX are trending on Yahoo Finance and moving on remarkably heavy trading volume Friday, despite a lack of company-specific news.
According to data from Benzinga Pro, more than 45 million shares have already been traded in the session, compared to the stock's 100-day average of just over 200 thousand shares.
Xortx Therapeutics is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection.
Related News: What's Going On With Bitcoin Mining Stocks Marathon Digital And Riot Platforms?
XRTX Price Action: According to Benzinga Pro, Xortx Therapeutics shares are up 52% at 53 cents at the time of publication.
Let's see what happens. The transaction has not closed.
Heading to FDA phase II trial. Long ways to go before FDA phase III approval for marketplace.
Shares of Lipella Pharmaceuticals Inc. (LIPO) rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company's investigational new drug application for its oral lichen planus treatment was approved by the U.S. Food and Drug Administration. Trading volume in the stock, which was the best performer on the major U.S. exchanges, blasted higher to 30.7 million shares, compared with the full-day average of about 6,400 shares. The stock has soared 150% in the three days since it last closed below the $1 mark, and has run up 164% amid a six-day winning streak. as Lipella described, OLP is a chronic, inflammatory autoimmune oral muscosal disease. It is a "highly morbid" condition with malignant potential that affects between 1% and 4% of the world population. Lipella's stock has now gained 18.6% over the past three months, but was still 57% below its initial public offering price of $5.75; the company went public on Dec. 20.
-Tomi Kilgore
For more from MarketWatch: http://www.marketwatch.com/newsviewer
CNXA is a great $$$$$ opportunity!
Bought .25 & .26 > MTNB is a great $$$$$ opportunity!
If I were a psychologist, I would tell these eco-anxiety laden kids to grow up , and plant a tree. The leaves thrive on CO2.
Possibly WW3. And Biden has emptied 75% of SPR.
Congrats on MTNB >
Huge conference starts today. > It's exciting to share the ongoing, consistent positive clinical impact of our broad-spectrum, fast-acting oral MAT2203, especially with a major infectious disease conference, IDWeek, kicking off today," said Theresa Matkovits, PhD, Chief Development Officer at Matinas. "We look forward to advancing MAT2203 into a Phase 3 registration trial to evaluate its potential in patients suffering from invasive aspergillosis who have limited or no treatment options. We believe that oral, effective, and safe MAT2203, if approved, would represent a dramatic improvement to current clinical standard of care and become the treatment of choice for patients and physicians battling invasive fungal infections. We are grateful to the participants in our Expanded Access program and to their physicians for recognizing the clinical potential of MAT2203 in treating a broad spectrum of invasive fungal infections."
What a great $$$$$ opportunity!
MTNB
That's funny!
"Joe Biden is neither physically nor cognitively up to the task of Commander in Chief in a crisis. He has more or less disappeared other than offering an occasionally brief appearance where he mumbles about standing with Israel and then vanishes again."
Those ho-tt-ies keep butt-dialing me! Nice trades!
Shiner Brewery started in 1909. Shiner beer is a staple in the Lone Star State, and every drop is brewed out of the Spoetzl Brewery in Shiner, Texas. The brewery is owned by the Gambrinus Company, based in San Antonio, and with each glass of Shiner beer comes a taste of history and pride.
Gritstone Bio shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7. >>>>> GRTS <<<<<
Benzinga
Mulberry Street in lower Manhattan, The spagh-etto!
Share price holding in AH . Let's see how she runs tomorrow.
Maybe government grants don't count in totaling yearly revenues ! > $$$$$
Horrible Revenues > According to MarketWatch, GRTS annual revenue averages $11,000. per employee.
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens, peptides that are presented on cancer cells when certain mutations occur in tumor DNA.
"Drill baby Drill!" > Legal action has been taken by Louisiana, the American Petroleum Institute (API), and Chevron and Shell oil companies against the Biden administration in relation to Lease Sale 261.
ATLANTA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced it has received 510(k) Clearance from the United States Food and Drug Administration (FDA) for FemaSeed(R), an innovative infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube.
In recent decades, infertility has affected an increasing number of women - estimated at 10 million in the United States according to the Center for Disease Control (CDC). Despite incremental advancements, there have been no recent meaningful affordable options. FemaSeed(R) Intratubal Insemination is a type of an intrauterine insemination procedure that is less invasive than in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), which we expect would reduce the chances of procedural complications.
"We are thrilled to receive 510(k) Clearance from FDA for FemaSeed(R), an innovative infertility treatment designed to deliver sperm directly to where conception occurs," said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. "This FDA 510(k) Clearance of FemaSeed demonstrates our successful collaborative efforts with the FDA to bring forward new technology that will address the significant unmet need for less burdensome infertility treatments."
Femasys is creating accessible options for women, as exemplified with FemaSeed(R), now an FDA-cleared infertility treatment, and its lead product candidate, FemBloc(R) in late-stage clinical development for permanent birth control. The Company is commercializing complementary diagnostic products that were internally developed through its in-house manufacturing capabilities, with regulatory approvals in the U.S., Canada and other countries outside the U.S. The FemaSeed procedure works synergistically with FemVue(R), Femasys' FDA-cleared diagnostic device that enables an in-office ultrasound assessment of the fallopian tubes and serves to provide an infertility diagnosis prior to FemaSeed.
Ms. Lee-Sepsick continued, "In recent years, there has been a sharp decline in fertility rates with a downward trajectory of sperm counts and record low birth rates. At this critical time, we are incredibly gratified that women and couples in the United States struggling with infertility will now have access to a new cost-effective infertility treatment option, in addition to the diagnostic solutions we have already made available."
About FemaSeed(R)
FemaSeed is an innovative infertility treatment designed to deliver sperm to the fallopian tube where conception occurs. It is intended to enhance natural fertilization and provide a first-line treatment option for infertility. FemaSeed is less invasive and more affordable than assisted reproduction procedures, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Femasys is supporting an ongoing pivotal clinical trial specific for male factor infertility. FemaSeed has achieved U.S. FDA clearance and regulatory approval in Canada.
About Femasys
Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary late-clinical stage product candidate and FDA-cleared, innovative therapeutic and diagnostic products. Femasys' FemBloc(R) permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. Femasys' FemaSeed(R) Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is now FDA-cleared (and also approved in Canada). The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada and other non-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. The Company's diagnostic products include FemVue(R) for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath(R), an intrauterine catheter for selective fallopian tube evaluation, and FemCerv(R), an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "pending," "intend," "believe," "potential," "hope," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
917-741-7792
chuck@lifesciadvisors.com
1.23 > AH high! Great news out!
The company is gearing up its Suwanee GA. operations facility, with a number of job openings. Looking for exponential revenue growth.
Femasys Price Target Maintained With a $10.00/Share by Chardan Capital.
Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination
9:01 am ET September 22, 2023 (Globe Newswire) Print
GlobeNewswireSeptember 22, 2023
SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (Nasdaq: MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction").
Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.
At the debut of trading, there will be a pro forma enterprise value of approximately $720 million. Existing Conduit Pharmaceuticals shareholders will own approximately 90% of the combined company's common stock issued and outstanding as of the closing.
Immediately prior to completion of the Transaction, MURF closed the previously announced investment by a single institutional investor, which purchased $20.0 million of MURF's units at a price of $10.00 per unit in a private placement. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock (the "Offering"). The warrants have an exercise price of $11.50, are exercisable after 30 days after the completion of the business combination and expire five years after the completion of the Transaction. Together, the Transaction and the Offering, provide Conduit with approximately $20 million, after giving effect to Murphy Canyon stockholder redemptions and before payment of Transaction and Offering expenses.
The Transaction was completed on September 22, 2023
In connection with the completion of the Transaction, MURF changed its name to Conduit Pharmaceuticals Inc. The shares of common stock of the combined company ("Conduit") are expected to begin trading on September 25, 2023, under the new ticker symbol "CDT" on The Nasdaq Global Market and the warrants under the new ticker symbol "CDTTW" on The Nasdaq Capital Market.
Management
Conduit Pharmaceuticals is led by a team of pharmaceutical industry veterans. Dr. Dave Tapolczay, former CEO of LifeArc and Worldwide Head of Chemistry at Zeneca Agrochemicals, is the Chief Executive Officer and a member of the Board of Directors. Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer, serves as Non-Executive Chair of the Board of Directors.
Dr. Tapolczay commented, "By acquiring rights to develop assets that have successfully completed Phase 1 trials from large pharmaceutical companies, we believe that we may dramatically reduce risks inherent in the traditional biotech model."
Dr. Lewis-Hall added, "Conduit's model positions it as a trailblazer in the industry: providing a platform to move deprioritized assets forward by way of a lean and focused pathway. I am excited about Conduit's potential to bring new treatments to patients that need them."
Jack Heilbron, the former Chairman and CEO of MURF, noted, "We continue to be impressed with Conduit's management team, and its plans as a public company. We expect that their novel approach to development of deprioritized assets will bring many new growth opportunities."
Advisors
A.G.P./Alliance Global Partners acted as the exclusive financial advisor to Conduit Pharmaceuticals in connection with the Transaction and as the sole placement agent to MURF in connection with the Offering. Sichenzia Ross Ference LLP acted as legal counsel to MURF. Thompson Hine LLP and Ogier (Cayman) LLP acted as legal counsel to Conduit Pharmaceuticals.
About Conduit
Conduit is a disease agnostic life science company providing an efficient model for compound development. Conduit is a departure from the traditional pharma/biotech business model whereby, typically companies shepherd their assets through regulatory approval, Conduit acquires assets that are Phase II-ready and then seeks an exit through third-party license deals following successful clinical trials. Conduit is led by a highly experienced team of pharmaceutical executives, including Dr. David Tapolczay and Dr. Freda Lewis-Hall, and was established to fund the development of clinical molecules licensed from major pharmaceutical companies.
About MURF
Prior to the business combination, MURF was a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Management was led by Jack Heilbron, Chief Executive Officer and Chairman of the Board of Directors. MURF was sponsored by Murphy Canyon Acquisition Sponsor, LLC, a wholly owned subsidiary of Presidio Property Trust, Inc. (Nasdaq: SQFT).
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated product candidates, and expected use of proceeds, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to obtain or maintain the listing of Conduit's securities on Nasdaq following the business combination; the risk that the business combination disrupts current plans and operations of Conduit as a result of the announcement and consummation of the business combination; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities; costs related to the business combination; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus relating to the business combination, including those under "Risk Factors" therein, and in other filings with the SEC made by MURF. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law. Conduit assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.
Contacts
Sean Leous
ICR Westwicke
sean.leous@westwicke.com
Adam Sragovicz
Conduit Pharmaceuticals Inc.
as@conduitpharma.com
Conduit is led by highly experienced pharmaceutical executive: Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer Inc.
MURF up 55% @ 20.00
Nice premarket trades!!!!! > Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced that after careful consideration and evaluation of potential strategic alternatives to enhance the Company's value, the Board of Directors has approved a plan to proceed with a spinout to Neptune shareholders of a majority of its equity interest in Sprout Organics ("Sprout"), an organic baby food and toddler brand. Upon completion of the spinout, which would follow the previously announced exchange by Neptune of existing Sprout debt for Sprout equity, pursuant to the term sheet entered into with Morgan Stanley as previously announced on August 17, 2023, it is anticipated that Neptune would spinout a majority of its equity interest in Sprout to current Neptune shareholders, and Neptune would keep a retained interest of approximately 10-15%.
The Company believes there are many benefits in proceeding with the contemplated spinout transaction, including reducing Neptune's operating costs and cash requirements and generally reducing Neptune's debt exposure, such that Neptune's overall financial position and cash flows would be improved.
Neptune will provide updates when further details of the proposed spinout transaction are determined. Neptune continues to evaluate additional available strategic options for the Company to unlock and maximize shareholder value, including strategic business and financial alternatives, which may include, but is not limited to, the monetization of assets, strategic partnerships, etc.
AH kaboomer! > Avinger In Filing, Said The Aggregate Market Value Of Our Outstanding Common Stock Held By Non-affiliates Is $9,846,526, Based On 625,208 Shares Of Outstanding Common Stock Held By non-affiliates As Of September 18, 2023 And A Price/Share Of $15.7492,
Benzinga
EVs with batteries will be looked at as the 8-track or cassette players of the past by 2030. So many charging stations are being damaged or destroyed. Thieves take the stolen various metal components to scrap yards.
I wonder what ARK MGMT. predicts a year from now. If all the oil pipelines are reopened in January 2025 , new gas engines and diesel engines vehicles sales will skyrocket.
EV sales will crater. ARK Investment Management predicts Tesla will reach a $2,000 per share price in 2027 and sales between $10.3 million and $20.7 million.
"Lying dog-faced pony soldier" !